Parth Sarthi Sen Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Parth Sarthi Sen Gupta has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Malay Kumar Rana
Physical and Biomolecular Research Lab Department of Chemical Sciences Indian Institute of Science Education and Research (IISER) Berhampur Ganjam Odisha India
14 shared publications - Amal Kumar Bandyopadhyay
Department of Biotechnology, The University of Burdwan, Burdwan, West Bengal, India
13 shared publications Saroj Kumar Panda
Department of Chemistry and Biochemistry, University of Texas at Arlington, Arlington, USA
10 shared publicationsRifat Nawaz Ul Islam
Department of Zoology, The University of Burdwan, East Burdwan, West Bengal, India
7 shared publicationsSatyaranjan Biswal
Department of Chemical Sciences, Indian Institute of Science Education and Research (IISER), Berhampur 760010, Odisha, India
7 shared publicationsArnab Nayek
Department of Biotechnology, The University of Burdwan, Bardhaman, West Bengal, India
5 shared publications
Latest Publications
- 30 October 2026
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 32 (11) , 453
Identification of broad-spectrum inhibitors for the cryptic binding site of SARS-CoV-2 NSP1 across multiple variants using molecular dynamics simulation
- 30 October 2026
- Published by Springer Nature in Journal of Molecular Modeling
- Vol. 32 (11) , 453
Identification of broad-spectrum inhibitors for the cryptic binding site of SARS-CoV-2 NSP1 across multiple variants using molecular dynamics simulation
- 10 September 2026
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- p. 1-28
Mechanistic insights into Mfd inhibition by pharmacophore-guided ligands using molecular and steered molecular dynamics simulations
1. Antimicrobial resistance (AMR) is a serious global health challenge of the twenty first century, resulting in an estimated 1.3 million deaths per year with an approximate global economic burden ...
- 10 September 2026
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- p. 1-28
Mechanistic insights into Mfd inhibition by pharmacophore-guided ligands using molecular and steered molecular dynamics simulations
1. Antimicrobial resistance (AMR) is a serious global health challenge of the twenty first century, resulting in an estimated 1.3 million deaths per year with an approximate global economic burden ...
- 13 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2654-2657
Fibrinogen as a Molecular Bridge Linking SARS-CoV-2 Immune Evasion and Endothelial Access?
SARS-CoV-2 exploits multiple cellular entry routes. Beyond ACE2-mediated entry, we propose that the spike protein binds fibrinogen not only to facilitate immune evasion but also to position the receptor-binding domain for integrin-mediated uptake. This molecular bridge may enhance viral RNA delivery to endothelial cells. Targeting the spike protein–fibrinogen interface could open new therapeutic avenues for acute and post-COVID vascular disease.
- 13 August 2026
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (9) , 2654-2657
Fibrinogen as a Molecular Bridge Linking SARS-CoV-2 Immune Evasion and Endothelial Access?
SARS-CoV-2 exploits multiple cellular entry routes. Beyond ACE2-mediated entry, we propose that the spike protein binds fibrinogen not only to facilitate immune evasion but also to position the receptor-binding domain for integrin-mediated uptake. This molecular bridge may enhance viral RNA delivery to endothelial cells. Targeting the spike protein–fibrinogen interface could open new therapeutic avenues for acute and post-COVID vascular disease.
- 24 April 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 209, 111701
Integrated experimental and computational evaluation of novel benzopyran-2-one congeners as reactive oxygen species scavengers in inflammation
- 24 April 2026
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 209, 111701
Integrated experimental and computational evaluation of novel benzopyran-2-one congeners as reactive oxygen species scavengers in inflammation
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (2) , 527-543
Decoding Ceftazidime-Avibactam Resistance in Newly Identified Klebsiella pneumoniae Carbapenemase (KPC) 107 Variant by Modulating the Active Site Environment
Antibiotic resistance is a serious health concern worldwide, predominantly driven by β-lactamase enzymes that can inactivate most prescribed β-lactam drugs. Carbapenemases are specialized β-lactamases that hydrolyze carbapenems, considered last-resort antibiotics. Insertion variants of Klebsiella pneumoniae carbapenemase (KPC) play a major role in this threat, showing alarming resistance to ceftazidime-avibactam (CZA), a key combination therapy to treat this menace. KPC-107 is a variant with an exceptional 28-residue insertion raised by duplication mutation (Ser-Ser-Pro-Arg-Ala-Val-Thr-Glu-Ser-Leu-Gln-Lys-Leu-Thr-Leu-Gly-Ser-Ala-Leu-Ala-Ala-Pro-Gln-Arg-Gln-Gln-Phe-Val) between Ambler positions 180 and 181, conferring resistance to CZA. Our study employs comprehensive biophysical, biochemical, and biological analyses accompanied by molecular docking and MD simulations, reporting that KPC-107 exhibits 10 times enhanced catalytic efficiency and 4-fold increased MIC value for ceftazidime compared to KPC-2, while its activity against other tested β-lactams is diminished. The reduced Ki value (0.23 ± 0.05 μM) of avibactam against KPC-107, in contrast with KPC-2 (Ki = 0.83 ± 0.1 μM), is further explained by carbamylation and decarbamylation rates. Insertion-induced active site modification might lead to a better binding with ceftazidime, which is reduced in the case of avibactam, which could possibly explain the contrasting behavior of KPC-107 against these ligands, as confirmed by fluorescence spectroscopy and isothermal titration calorimetry (ITC). Molecular docking and MD simulations, including free energy landscape (FEL), principal component analysis (PCA), and radial distribution function (RDF), may further support the binding affinity and the mechanisms underlying ceftazidime resistance. Our findings suggest that KPC-107 adapts distinct mechanistic strategies to evade CZA armor by enhanced ceftazidime hydrolysis while compromising increased inhibition by avibactam, strengthening its role in antibiotic resistance evolution.
- 19 December 2025
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (2) , 527-543
Decoding Ceftazidime-Avibactam Resistance in Newly Identified Klebsiella pneumoniae Carbapenemase (KPC) 107 Variant by Modulating the Active Site Environment
Antibiotic resistance is a serious health concern worldwide, predominantly driven by β-lactamase enzymes that can inactivate most prescribed β-lactam drugs. Carbapenemases are specialized β-lactamases that hydrolyze carbapenems, considered last-resort antibiotics. Insertion variants of Klebsiella pneumoniae carbapenemase (KPC) play a major role in this threat, showing alarming resistance to ceftazidime-avibactam (CZA), a key combination therapy to treat this menace. KPC-107 is a variant with an exceptional 28-residue insertion raised by duplication mutation (Ser-Ser-Pro-Arg-Ala-Val-Thr-Glu-Ser-Leu-Gln-Lys-Leu-Thr-Leu-Gly-Ser-Ala-Leu-Ala-Ala-Pro-Gln-Arg-Gln-Gln-Phe-Val) between Ambler positions 180 and 181, conferring resistance to CZA. Our study employs comprehensive biophysical, biochemical, and biological analyses accompanied by molecular docking and MD simulations, reporting that KPC-107 exhibits 10 times enhanced catalytic efficiency and 4-fold increased MIC value for ceftazidime compared to KPC-2, while its activity against other tested β-lactams is diminished. The reduced Ki value (0.23 ± 0.05 μM) of avibactam against KPC-107, in contrast with KPC-2 (Ki = 0.83 ± 0.1 μM), is further explained by carbamylation and decarbamylation rates. Insertion-induced active site modification might lead to a better binding with ceftazidime, which is reduced in the case of avibactam, which could possibly explain the contrasting behavior of KPC-107 against these ligands, as confirmed by fluorescence spectroscopy and isothermal titration calorimetry (ITC). Molecular docking and MD simulations, including free energy landscape (FEL), principal component analysis (PCA), and radial distribution function (RDF), may further support the binding affinity and the mechanisms underlying ceftazidime resistance. Our findings suggest that KPC-107 adapts distinct mechanistic strategies to evade CZA armor by enhanced ceftazidime hydrolysis while compromising increased inhibition by avibactam, strengthening its role in antibiotic resistance evolution.
- 30 September 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (8) , 3964-3985
Mechanistic insights into ESBL activity of subclass A2 in Class A beta-lactamase revealing a distinct strategy towards conferring drug resistance
The twenty first century has witnessed challenges with antimicrobial resistance (AMR) emerging as a critical global threat. Among its most concerning is antibiotic resistance (ABR), highly linked to beta-lactamases. Among others, Class A beta-lactamases, present significantly with functional diversity, although ESBLs are one of the major concerns. A key defence mechanism in Gram-negative bacteria is the overexpression of ESBLs (Extended spectrum beta-lactamases) which spread across the bacterial population through horizontal gene transfer causes serious nosocomial infections. Since ESBLs have developed to increase their substrate specificity and hydrolyse most cephalosporins, penicillins, and monobactams, research into them is urgently needed.However, despite attempts functional classification, based on sequence identity, fold similarity, the presence or absence of insertions, particularly in loop regions and mode of action, a universally accepted framework remains elusive. Previous studies have broadly categorized Class A beta-lactamases into subclasses A1 and A2, yet the mechanistic intricacies of subclass A2 only as ESBL demand a more nuanced, multilevel analysis, underlying their role in antibiotic resistance. To bridge this knowledge gap, we employed on a comprehensive investigation encompassing sequence, structure, molecular docking, and dynamic analyses to elucidate the mechanistic approach of antibiotic resistance profiles for these two subclasses. Our sequence and structural studies revealed differences, particularly in insertions, structural alignments, and loop regions, including the omega loop and loops near the active site. Molecular docking study demonstrated better binding of the bigger substrate in the active site cavity of A2 subclass representatives. Dynamic analyses further confirmed our findings, employing root mean square deviation (RMSD), root mean square fluctuation (RMSF), flexibility of the extended and omega loops, radius of gyration (Rg), solvent-accessible surface area (SASA), clustering, hydrogen bonding patterns, principal component analysis (PCA), and free energy landscape (FEL). This study provides insights into the molecular distinctions and resistance mechanisms of these subclasses, paving the way for advanced research in antibiotic resistance and strengthening novel therapeutic strategies.
- 30 September 2025
- Published by Taylor & Francis in Journal of Biomolecular Structure and Dynamics
- Vol. 44 (8) , 3964-3985
Mechanistic insights into ESBL activity of subclass A2 in Class A beta-lactamase revealing a distinct strategy towards conferring drug resistance
The twenty first century has witnessed challenges with antimicrobial resistance (AMR) emerging as a critical global threat. Among its most concerning is antibiotic resistance (ABR), highly linked to beta-lactamases. Among others, Class A beta-lactamases, present significantly with functional diversity, although ESBLs are one of the major concerns. A key defence mechanism in Gram-negative bacteria is the overexpression of ESBLs (Extended spectrum beta-lactamases) which spread across the bacterial population through horizontal gene transfer causes serious nosocomial infections. Since ESBLs have developed to increase their substrate specificity and hydrolyse most cephalosporins, penicillins, and monobactams, research into them is urgently needed.However, despite attempts functional classification, based on sequence identity, fold similarity, the presence or absence of insertions, particularly in loop regions and mode of action, a universally accepted framework remains elusive. Previous studies have broadly categorized Class A beta-lactamases into subclasses A1 and A2, yet the mechanistic intricacies of subclass A2 only as ESBL demand a more nuanced, multilevel analysis, underlying their role in antibiotic resistance. To bridge this knowledge gap, we employed on a comprehensive investigation encompassing sequence, structure, molecular docking, and dynamic analyses to elucidate the mechanistic approach of antibiotic resistance profiles for these two subclasses. Our sequence and structural studies revealed differences, particularly in insertions, structural alignments, and loop regions, including the omega loop and loops near the active site. Molecular docking study demonstrated better binding of the bigger substrate in the active site cavity of A2 subclass representatives. Dynamic analyses further confirmed our findings, employing root mean square deviation (RMSD), root mean square fluctuation (RMSF), flexibility of the extended and omega loops, radius of gyration (Rg), solvent-accessible surface area (SASA), clustering, hydrogen bonding patterns, principal component analysis (PCA), and free energy landscape (FEL). This study provides insights into the molecular distinctions and resistance mechanisms of these subclasses, paving the way for advanced research in antibiotic resistance and strengthening novel therapeutic strategies.
- 7 July 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (17) , 3312-3322
Dual Inhibition of IDO1 and TDO: A Unified Therapeutic Strategy to Combat Alzheimer’s Disease and Cancer
The kynurenine pathway, regulated by the enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), plays a pivotal role in immune regulation and neuroinflammation in human. Dysregulation of this pathway has been strongly associated with the pathogenesis of Alzheimer's disease and various cancers. In this study, we present a comprehensive computational investigation to identify potential dual inhibitors of IDO1 and TDO, aiming to simultaneously target the molecular mechanisms underlying these two devastating conditions. A natural compound library was subjected to an integrated screening approach involving virtual screening, ADMET profiling, and molecular dynamics simulations. Our analysis identifies hydroxy sanguinarine, chelirubine, 17-decarboxy-neobitanin, and epicatechin-5-O-glucuronide as the potent leads that exhibited strong binding affinity, favorable pharmacokinetic properties, and stable protein-ligand interactions with both the enzymes. Dual inhibition of IDO1 and TDO is proposed to restore immune surveillance in cancer while mitigating neurodegenerative processes in Alzheimer's disease via modulation of the kynurenine pathway. To the best of our knowledge, this is the first attempt exploring the dual targeting of IDO1 and TDO as a unified therapeutic strategy for combating both Alzheimer's disease and cancer. These findings would provide information for future experimental validation and the development of innovative multitarget therapeutics.
- 7 July 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (17) , 3312-3322
Dual Inhibition of IDO1 and TDO: A Unified Therapeutic Strategy to Combat Alzheimer’s Disease and Cancer
The kynurenine pathway, regulated by the enzymes indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO), plays a pivotal role in immune regulation and neuroinflammation in human. Dysregulation of this pathway has been strongly associated with the pathogenesis of Alzheimer's disease and various cancers. In this study, we present a comprehensive computational investigation to identify potential dual inhibitors of IDO1 and TDO, aiming to simultaneously target the molecular mechanisms underlying these two devastating conditions. A natural compound library was subjected to an integrated screening approach involving virtual screening, ADMET profiling, and molecular dynamics simulations. Our analysis identifies hydroxy sanguinarine, chelirubine, 17-decarboxy-neobitanin, and epicatechin-5-O-glucuronide as the potent leads that exhibited strong binding affinity, favorable pharmacokinetic properties, and stable protein-ligand interactions with both the enzymes. Dual inhibition of IDO1 and TDO is proposed to restore immune surveillance in cancer while mitigating neurodegenerative processes in Alzheimer's disease via modulation of the kynurenine pathway. To the best of our knowledge, this is the first attempt exploring the dual targeting of IDO1 and TDO as a unified therapeutic strategy for combating both Alzheimer's disease and cancer. These findings would provide information for future experimental validation and the development of innovative multitarget therapeutics.
- 23 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 619, 217647
Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
- 23 March 2025
- Published by Elsevier in Cancer Letters
- Vol. 619, 217647
Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (4) , 1182-1184
Spike Protein–Fibrinogen Interaction: A Novel Immune Evasion Strategy of SARS-CoV-2?
The host protein fibrinogen has been found to interact with the N-terminal domain (NTD) of the spike protein in SARS-CoV-2. However, the evolutionary benefit of this binding to the virus still remains unclear. Herein, we put forward with rationale and supporting evidence that the binding of fibrinogen to its more conserved NTD is an immune evasion strategy adopted by the virus to outsmart the NTD targeted neutralizing antibodies.
- 19 March 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (4) , 1182-1184
Spike Protein–Fibrinogen Interaction: A Novel Immune Evasion Strategy of SARS-CoV-2?
The host protein fibrinogen has been found to interact with the N-terminal domain (NTD) of the spike protein in SARS-CoV-2. However, the evolutionary benefit of this binding to the virus still remains unclear. Herein, we put forward with rationale and supporting evidence that the binding of fibrinogen to its more conserved NTD is an immune evasion strategy adopted by the virus to outsmart the NTD targeted neutralizing antibodies.